A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors

Exclusion Criteria

• •1. Anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks or 5 half lives, whichever is shorter, prior to initiation of study treatment
• •2. Active autoimmune disease or a history of severe autoimmune disease or syndrome
• •3. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
• •4. Inability to comply with study and follow-up procedures.
• •5. Pregnancy, lactation, or breastfeeding women.
• •6. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina.
• •7. Known clinically significant liver disease,
• •8. Major surgical procedure within 28 days prior to initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study.
• •9. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.